Overview

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

Status:
Withdrawn

Trial end date:
2019-06-01

Target enrollment:

Participant gender:

Summary

This is a phase II study to determine the immunogenicity and efficacy of a vaccine composed of tumor associated long synthetic peptides mixed with Montanide ISA-51 VG administered with polyinosinic-polycytidylic acid - poly-L-lysine carboxymethylcellulose (Poly-ICLC) and bevacizumab in adults with recurrent glioblastoma.

Phase:

Phase 2

Details

Lead Sponsor:

New York University School of Medicine
NYU Langone Health

Collaborators:

MOUNT SINAI HOSPITAL
Mount Sinai Hospital, New York

Treatments:

Adjuvants, Immunologic
Antibodies, Monoclonal
Bevacizumab
Keyhole-limpet hemocyanin
Poly ICLC
Vaccines